DACOGEN is a prescription medicine for patients with myelodysplastic syndrome (MDS), including previously treated and untreated MDS and de novo (cause unknown) and secondary (treatment-related) MDS of all French-American- British (FAB) subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System (IPSS) groups.
I have several GDI engine customers into pre, mid 100K mile intervals, NO issues, we suggest 3K mile oil change intervals, add fuel system cleaner at each oil change and change pcv valves at 30 K mile intervals, None of these customer have developed engine performance, milage reduction or misfire codes. Nothing has change pay me a little now or a lot later. All of the GDI problems I have seen are on engines with poor basic maintenance. (IE. extended service (wroing oil or extended services) Fuel pump, misfire issues and performance issues)
18 trials (1179 participants) were included in this updated review . The injection sites varied from epidural sites and facet joints (. intra-articular injections, peri-articular injections and nerve blocks) to local sites (. tender- and trigger points). The drugs that were studied consisted of corticosteroids, local anesthetics and a variety of other drugs. The methodological quality of the trials was limited with 10 out of 18 trials rated as having a high methodological quality. Statistical pooling was not possible due to clinical heterogeneity in the trials. Overall, the results indicated that there is no strong evidence for or against the use of any type of injection therapy .